Your search for oral corticosteroids returned 24 results

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 VOYAGE trial.

Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.

The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…

The CLEAR study compared clinical outcomes and health resource usage in patients with severe asthma who continued, switched, or stopped their biologic treatment.

The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Findings may help with decision-making in this high-risk patient population.

The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.

Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.

The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.

Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).